Johnson & Johnson’s Covid-19 vaccine is safe and effective, U.S. regulators said, a key milestone on the path toward giving Americans access to the first such shot to work in a single dose.
The vaccine was 72% effective in the U.S.-based trial arm of its global study of more than 43,000 participants, Food and Drug Administration staff wrote in a document that summarized the company’s results and confirmed findings J&J released earlier this month.
Vaccines from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE were authorized by the FDA in December, just before the first major coronavirus variants were seen in the U.S. Since then, mutant versions have become a major concern, and J&J’s vaccine has been found to be less effective in South Africa and Latin America, where two quickly spreading versions were identified. Another variant that first arose in the U.K., called B.1.1.7, has been seen at even higher levels in the U.S.
The FDA’s analysis found the shot to have a favorable safety profile. There were no Covid-related deaths in the vaccinated group, the staff wrote, nor any other safety concerns that would preclude an emergency-use authorization. The agency lacked data to determine whether the J&J vaccine prevented asymptomatic cases, the report said.
Agency officials prepared the document ahead of a meeting Friday where external advisers will make a non-binding recommendation as to whether the vaccine should be authorized. J&J’s rose 1.6% in pre-market trading on Wednesday.
If J&J’s shot is quickly authorized after Friday’s advisory panel meeting, as the other two vaccines were, the company will initially be able to provide 4 million doses, according to Richard Nettles, vice president of U.S. medical affairs for J&J’s Janssen Infectious Diseases and Vaccines unit.
Those doses are well short of J&J’s initial promise to the U.S. government to supply 12 million doses by the end of February. Speaking in a Congressional hearing on Tuesday, Nettles said the company continues to ramp up production facilities, aiming to have seven manufacturing sites active by mid-year.
Subscribe to our YouTube channel: [ Ссылка ]
Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
To watch complete coverage on Bloomberg Quicktake 24/7, visit [ Ссылка ], or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.
Connect with us on…
YouTube: [ Ссылка ]
Breaking News on YouTube: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
